Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH [Phase 2]

View source ↗

Summary

Phase 2 trial assessing CS0159 in nonalcoholic steatohepatitis (NASH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• CS0159

Snippet

Sponsor: Cascade Pharmaceuticals, Inc | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED